CTX.TO WACC - Weighted Average Cost of Capital

The WACC of Crescita Therapeutics Inc (CTX.TO) is 6.7%.

The Cost of Equity of Crescita Therapeutics Inc (CTX.TO) is 6.80%.

The Cost of Debt of Crescita Therapeutics Inc (CTX.TO) is 5.40%.

	Range	Selected
Cost of equity	5.40% - 8.20%	6.80%
Tax rate	10.50% - 18.40%	14.45%
Cost of debt	4.00% - 6.80%	5.40%
WACC	5.4% - 8.1%	6.7%

WACC

CTX.TO WACC calculation

Category	Low	High

Long-term bond rate	3.2%	3.7%
Equity market risk premium	5.1%	6.1%
Adjusted beta	0.34	0.58

Additional risk adjustments	0.5%	1.0%
Cost of equity	5.40%	8.20%

Tax rate	10.50%	18.40%
Debt/Equity ratio	0.02	0.02
Cost of debt	4.00%	6.80%

After-tax WACC	5.4%	8.1%


Selected WACC	6.7%

CTX.TO's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for CTX.TO:

cost_of_equity (6.80%) = risk_free_rate (3.45%) + equity_risk_premium (5.60%) * adjusted_beta (0.34) + risk_adjustments (0.75%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.